EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Low-Dose Atropine 0.025% for Childhood Myopia Control: A Retrospective Review in Clinical Practice

Ng Kaiwen, Aaron Qi Yang Goh iD, Bryan Xiangrong Sim, Sri Yudah, Pauline Poh Lin Chan, Hla Myint Htoon, Audrey Wei Lin Chia

Journal of Clinical Medicine · 04.11.2026 · 15 (21) · 8587

DOI: 10.3390/jcm15218587 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 04.11.2026. Verfasst von Ng Kaiwen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ministry of Health Holdings Private Limited (MOHH), Singapore 139691, Singapore. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

In this retrospective audit, Atropine 0.025% eyedrops were evaluated in a clinical setting.

Method

Children aged 4–16 years, who were started on Atropine 0.025% with at least 6 months of follow-up, were included. A total of 588 eyes (299 children) were classified as treatment-naïve eyes started on Atropine 0.025% daily (Group A, n146), eyes progressing on Atropine 0.01% daily increased to 0.025% daily (Group B, n287) or combined with myopia control glasses (Group C, n66), and those stable on Atropine 0.01% twice daily converted to Atropine 0.025% daily (Group D, n89). Spherical equivalent (SE) and axial length (AL) were recorded from 6 months before treatment to 24 months after treatment began.

Result

Group A children were younger (8.4 ± 1.5 years), while Group D children were older (10.6 ± 1.59 years). Progression in the first 6 m was significantly less than that in 6 m prior in Groups A-C. At 1 year, a change in AL < 0.15 mm was noted in 41%, 49%, 50% and 35%, and a change in AL ≥ 0.30 mm was observed in 38%, 18%, 32% and 23% of eyes in Groups A, B, C and D, respectively. Treatment was increased in 37%, 34%, 12% and 41% of eyes over 2 years in Groups A, B, C and D, respectively. Mean progression at 2 years was −0.63 ± 0.86 D or 0.44 ± 0.31 mm, −0.39 ± 0.59 D or 0.30 ± 0.26 mm, −0.30 ± 0.48 D or 0.36 ± 0.40 mm, and −0.48 ± 0.54 D or 0.33 ± 0.22 mm in Groups A, B, C and D, respectively. Multivariate analysis suggested that progression was mainly associated with younger age.

Conclusions

Atropine 0.025% was a useful addition to myopia control, with some eyes requiring further modification in treatment.

Schlagwörter

Stichwörter der Autor:innen

atropinecombinationmyopia

Autor:innen und Institutionen

  • Ministry of Health Holdings Private Limited (MOHH), Singapore 139691, Singapore.
  • Singapore National Eye Centre (SNEC), Singapore 168751, Singapore.
  • Myopia Centre at Bedok, Singapore 460212, Singapore.
  • Singapore Eye Research Institute (SERI), Singapore 169856, Singapore.

ORCID-Profile: Aaron Qi Yang Goh

Zitieren

APA

Kaiwen, N., Goh, A. Q. Y., Sim, B. X., Yudah, S., Chan, P. P. L., Htoon, H. M., & Chia, A. W. L. (2026). Low-Dose Atropine 0.025% for Childhood Myopia Control: A Retrospective Review in Clinical Practice. Journal of Clinical Medicine, 15(21), 8587. https://doi.org/10.3390/jcm15218587

Vancouver

Kaiwen N, Goh AQY, Sim BX, Yudah S, Chan PPL, Htoon HM, et al. Low-Dose Atropine 0.025% for Childhood Myopia Control: A Retrospective Review in Clinical Practice. Journal of Clinical Medicine. 2026;15(21):8587. doi:10.3390/jcm15218587

BibTeX
@article{Kaiwen2026,
  author = {Kaiwen, Ng and Goh, Aaron Qi Yang and Sim, Bryan Xiangrong and Yudah, Sri and Chan, Pauline Poh Lin and Htoon, Hla Myint and Chia, Audrey Wei Lin},
  title = {Low-Dose Atropine 0.025% for Childhood Myopia Control: A Retrospective Review in Clinical Practice},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {21},
  pages = {8587},
  doi = {10.3390/jcm15218587}
}
Kostenlos starten →